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Calcium-binding protein S100A9 (MRP-14) induces antinociceptive eﬀect in an experimental model of painful sensibility and
participates of antinociception observed during neutrophilic peritonitis induced by glycogen or carrageenan in mice. In this study,
the direct antinociceptive role of the protein S100A9 in neutrophilic cell-free exudates obtained of mice injected with glycogen was
investigated. Mice were intraperitoneally injected with a glycogen solution, and after 4, 8, 24, and 48 hours, either the pattern of
cell migration of the peritoneal exudate or the nociceptive response of animals was evaluated. The glycogen-induced neutrophilic
peritonitis evoked antinociception 4 and 8 hours after inoculation of the irritant. Peritoneal cell-free exudates, collected in diﬀerent
times after the irritant injection, were transferred to naive animals which were submitted to the nociceptive test. The transference
of exudates also induced antinociceptive eﬀect, and neutralization of S100A9 activity by anti-S100A9 monoclonal antibody totally
reverted this response. This eﬀect was not observed when experiments were made 24 or 48 hours after glycogen injection. These
results clearly indicate that S100A9 is secreted during glycogen-induced neutrophilic peritonitis, and that this protein is respon-
sible by antinociception observed in the initial phase of inflammatory reaction. Thus, these data reinforce the hypothesis that the
calcium-binding protein S100A9 participates of the endogenous control of inflammatory pain.
Copyright © 2006 Rosana L. Pagano et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
Neutrophils, monocytes, and macrophages secret a variety of
biologically active products involved in distinct pathophys-
iologic types of response. That is the case of the calcium-
binding proteins S100A8 and S100A9 [1], both members
of the family of the S100 proteins [2], which are expressed
in diﬀerentiating cells of the myeloid lineage, in mature
neutrophils and monocytes, but absent in normal tissue
macrophages and lymphocytes [3, 4].
The S100A8/A9 proteins comprise 45% of the total pro-
teins in the cytosol of neutrophils and 1% in monocytes [5],
and can be found in a complex form called calprotectin [6].
S100A8 and S100A9 proteins are also described as p8 and p14
[7], L1 light and heavy chain [8], calgranulin A and B [9],
and MRP-8 and MRP-14 [10], respectively. Under inflam-
matory conditions and/or upon calcium mobilization they
are translocated from the cytosol to the cytoskeleton and to
cell plasma membrane [11, 12]. It has been demonstrated
that both proteins are secreted by activated monocytes via a
tubulin and PKC-dependent pathway [13]. In addition, the
heterodimer of these proteins binds arachidonic acid with
high aﬃnity in a calcium-dependent manner [14].
Although little is known about the biological function of
S100A8/A9, it has been demonstrated that in vitro the cal-
protectin has an antimicrobial eﬀect on several micro organ-
isms [6, 15], and induces apoptosis of various tumour cells
or normal fibroblasts in a zinc-reversible manner [16, 17].
S100A8/A9 complex is found in high concentrations in body
fluids of patients with acute and chronic diseases such as
chronic bronchitis, cystic fibrosis, and rheumatoid arthritis
[18], making this complex a useful biomarker of inflamma-
tory diseases [19]. An anti-inflammatory eﬀect of this com-
plex in a model of adjuvant-induced arthritis in the rat was
reported [20], suggesting a possible extra cellular role for
these proteins.
Independent expression and functioning of S100A9 pro-
tein have also been observed [10, 21]. This protein regulates
neutrophil adhesion to fibrinogen, selectively activates the
β2 integrin, Mac-1 [22] and deactivates BCG-activated peri-
toneal macrophages [23]. We have demonstrated a marked
antinociception eﬀect of S100A9 in a model of inflammatory
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pain [24]. Further, antinociception was detected in the
course of acute neutrophilic peritonitis induced by glycogen
and carrageenan, which were reverted by the treatment of an-
imals with a monoclonal antibody anti-S100A9, suggesting
that neutrophils in acute inflammation down-regulate the
nociceptive response via S100A9 activity [24, 25]. Recently,
we demonstrated that the C-terminus of S100A9 murine in-
hibits the spreading and phagocytic activities of adherent
peritoneal cells [26], cells involved in the nociceptive re-
sponse during the model of abdominal contortions in mice
[27]. Based on these data, in the present study we investi-
gated the antinociceptive eﬀect of the neutrophilic cell-free
exudate induced by glycogen, and the role of the calcium-
binding protein S100A9 in this eﬀect.
MATERIALS AND METHODS
Animals
Outbred male mice from the Swiss strain, weighing 20–25 g,
were used throughout this study. The animals were main-
tained under controlled light (12/12 hours) and temperature
(22   2ÆC) with free access to food and water. Throughout
the experiments, the animals were managed using the princi-
ples and guidelines published by the Committee for Research
and Ethical Issue of the International Association for Study of
Pain [28].
Glycogen-induced peritonitis
Mice were intraperitoneally (IP) injected with 500 μL of a 5%
solution of oyster glycogen type II (Sigma, Mo, USA) pre-
pared in sterile saline. Control animals were injected only
with saline. After 4, 8, 24, or 48 hours of glycogen solution
inoculation, mice were either sacrificed, in a CO2 chamber,
to evaluation of the peritoneal fluid or submitted to the no-
ciceptive test.
Nociception evaluation by the writhing test
The mouse writhing test used was based on the method of
Koster et al [29]. The abdominal contortions resulting from
intraperitoneal injection of acetic acid (0.6%; Merck, Darm-
stadt, Germany) at a dosage of 60mg/Kg (v/v) consist of con-
traction of the abdominal muscles with stretching of the hind
limb. The number of abdominal contortions was counted cu-
mulatively over a period of 20 minutes after acetic acid injec-
tion. The antinociceptive activity was expressed as the reduc-
tion in number of abdominal contortions in treated as com-
pared to control animals, injected with saline or only with
acetic acid.
Inflammatory cells characterization and cell-free
exudate collection
Mice injected with glycogen solution or sterile saline, af-
ter diﬀerent times, were sacrificed in a CO2 chamber and
their peritoneal cavities washed with 5mL of cold phosphate-
buﬀered saline (PBS) pH 7.4. After a gentle massage of the
abdominal wall, the peritoneal fluid was collected and the
total and diﬀerential counts of leukocytes were determined.
The leukocyte cell-free exudate supernatant was obtained
from the peritoneal fluid after two individual centrifuga-
tions (2000 rpm/10 min, 5ÆC). Supernatants assembled for
each time and group of the treatment were frozen (20ÆC)
and, in the moment of assay, were injected in naive animals
(200 μL/cavity) 30 minutes before of the evaluation of the
antinociceptive activity.
Monoclonal antibody (mAb)
Mouse mAb (IgG1) antihuman S100A9 (anti-MRP-14; BMA
Biomedicals AG, Switzerland) and goatmAb antimouse IgG1
(Sigma, Mo, USA) were used.
Adsorption of S100A9 of the inflammatory
cell-free exudates
mAb antimouse IgG1 (1mg/mL) in carbonate buﬀer (pH
9.5) was distributed in wells of 96-well ELISA plates
(100 μL/well) and incubated overnight at 4ÆC. These solu-
tions were removed and the wells were filled with 1% bovine
seric albumine (BSA) in PBS (200 μL/well) for 12 hours at
4ÆC. The wells were washed (three times) with PBS fol-
lowed by Twin 20 (0.5%) in PBS (two times) and replaced
with 200 μL of supernatants obtained from the inflamma-
tory cell-free exudate, after 4 or 8 hours of glycogen inocula-
tion, previously incubated with antihuman S100A9 (mouse
IgG1 isotype). The supernatants were adsorbed in tripli-
cate on antimouse IgG1-coated wells in 2-hour intervals,
and finally incubated on coated wells for 18 hours at 4ÆC.
These supernatants were frozen (20ÆC), and in the mo-
ment of assay were intraperitoneally injected in naive animals
(200 μL/cavity), 30 minutes before the nociceptive test.
Statistical analysis
Results are expressed as mean   standard errors of means
(SEM) and were compared by the Student t test or by analy-
sis of variance [30], followed by Duncan’s test [31]. A proba-
bility level of less than .05 was taken as significant (P < .05).
RESULTS
Glycogen-induced leukocyte migration
As we had previous evidence that neutrophils, via protein
S100A9 (MRP-14), mediate the antinociceptive eﬀect in a
neutrophilic peritonitis induced by glycogen [24], we first de-
cided to establish the leukocyte influx induced by the irritant.
Results confirmed our data and showed that the IP injection
of glycogen induced a significant number of polymorphonu-
clear cells in the peritoneal cavity of animals when com-
pared with controls. The maximal number of these cells was
observed 8 hours after the irritant injection (Figure 1(a)).
The number of mononuclear cells significantly decreased
4 and 8 hours after glycogen injection. Conversely it was
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Figure 1: Kinetics of leukocyte influx to peritoneal cavity of mice after IP injection of a glycogen solution (5%, 500 μL/animal). Number
of polymorphonuclear cells (PMN cells; (a)) and mononuclear cells (MN cells; (b)). Results are expressed in absolute numbers obtained in
relation to the total number of collected cells. Values represent mean values   SEM for 8–16 animals for each experimental time.  P < .05
in comparison with values obtained in control animals.
showed an increase of these cells after 48 hours of irritant
treatment (Figure 1(b)).
Glycogen-induced antinociceptive effect
To confirm the antinociceptive response observed after in-
traperitoneal glycogen injection, we submitted the animals to
the writhing test after glycogen injection. Results showed an
antinociceptive eﬀect, 4 and 8 hours after the irritant treat-
ment, when compared with animals previously injected with
saline or acetic acid alone (42 and 47% inhibition, resp.)
(Figure 2). It was also observed that the injection of glycogen
solution did not induce changes in the nociceptive response
of animals after 24 or 48 hours of treatment when compared
with control animals (Figure 2).
Transference of inflammatory cell-free exudate
To investigate if the antinociceptive factor was secreted by
migrated leukocytes after the glycogen inoculation, naive an-
imals were injected with cell-free exudate, obtained after dif-
ferent time intervals, and after 30 minutes evaluated in the
writhing test. Results show that the transference of cell-free
exudates induced antinociceptive eﬀect when they were ob-
tained 4 or 8 hours after glycogen injection (40 and 45% in-
hibition, resp.). The treatment of mice either with cell-free
exudate obtained 24 or 48 hours after the irritant injection or
with the supernatants obtained of animals injected only with
saline did not influence the nociceptive response (Figure 3).
Adsorption of S100A9 of the cell-free exudates
with antinociceptive effect
To investigate whether the antinociceptive eﬀect induced
by cell-free exudates obtained after 4 or 8 hours of the
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Figure 2: Eﬀect of glycogen on painful sensibility of mice evaluated
in the writhing test. The test was applied in diﬀerent times after IP
injection of glycogen (5%, 500 μL/animal). Controls were injected
only with acetic acid. Values represent the mean   SEM of 8–16 an-
imals for each group.  P < .05 in comparison with values obtained
in control animals.
glycogen injection was due to secretion of the S100A9 pro-
tein, mice were treated with cell-free exudates adsorpted of
this protein. Results show that adsorption of S100A9 from
these supernatants, using mAb anti-S100A9 (anti-MRP-14),
reverted the observed antinociceptive response (Figure 4).
Treatment of animals with this mAb alone or with nonre-
lated rat IgG, previously to the acetic acid injection, did not
alter the nociceptive response when compared with control
animals (data not shown).
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Figure 3: Eﬀect of cell-free exudates obtained 4, 8, 24 or 48 hours
after glycogen injection (Glycogen Sn) in naive animals submitted
to the writhing test. The exudate supernatants (200 μL/cavity) were
injected 30minutes before the test. Animals injected with super-
natants obtained after saline injection (Saline Sn) were also evalu-
ated. Controls were injected only with acetic acid. Values represent
the mean   SEM of 8–16 animals for each group.  P < .05 in com-
parison with values obtained in control animals.
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Figure 4: Eﬀect of adsorption of S100A9 of cell-free exudates ob-
tained 4 or 8 hours after glycogen injection (Gly Sn + anti-S100A9)
in naive animals submitted to the writhing test. The exudate su-
pernatants (200 μL/cavity) were injected 30 minutes before the test.
Animals injected with exudate supernatants not treated with mAb
anti-S100A9 (Gly Sn) were also evaluated. Controls were injected
only with acetic acid. Values represent the mean   SEM of 8–16 an-
imals for each group.  P < .05 in comparison with values obtained
in control animals.
DISCUSSION
Mediators secreted during inflammatory response are in-
volved in the control of painful response. In regard to that,
interleukin-4 (IL-4), IL-10, and IL-13 have the propriety of
limiting the inflammatory hyperalgesia inhibiting the pro-
duction of proinflammatory cytokines [32–35].
Proteins S100A8 and S100A9 comprise an important
group of proteins expressed by phagocytes during inflamma-
tory response [36], and are involved in the first line of defence
against this type response [37]. The S100A9 protein, specifi-
cally, play a role in the inflammatory reaction to lipopolis-
sacarides by inducing the release of neutrophils from the
bone marrow and directing their migration to the inflamma-
tory site, thus suggesting that it could represent a new class
of early cytokines involved in innate immune responses [38].
According to the evidence suggesting that S100A9 is a
proinflammatory protein [36], our group have proposed
that this protein is endowed with antinociceptive activity
in inflammatory pain model [24]. It was also observed the
participation of S100A9 in antinociception observed during
acute inflammatory peritonitis induced by glycogen or car-
rageenan in mice [24, 25]. Recently, we demonstrated that
the C-terminus of this protein is involved either with the
antinociceptive eﬀect on hyperalgesia induced by protease
[39], or with the inhibition of the phagocytosis and spread-
ing activities of adherent peritoneal cells [26], cells respon-
sible by the writhing nociceptive response [27]. Based on
these data, we decided to investigate if the S100A9 is secreted
during glycogen-induced neutrophilic peritonitis, and if this
protein directly acts in the antinociceptive eﬀect observed in
this model of acute inflammation.
A direct correlation between the number of neutrophils
in the peritoneal cavity after glycogen treatment and the
maximal antinociceptive response was observed, as previ-
ously described [24]. In agreement with data obtained by
Pagano et al [25] our results strongly suggest that these cells
could be involved in the control of inflammatory pain, pos-
sibly through S100A9 protein action.
The antinociceptive eﬀect observed after leukocyte cell-
free exudate transfer, obtained after 4 or 8 hours of glyco-
gen injection to naive animals, confirmed that migrated cells
secrete the antinociceptive factor in acute phase of inflam-
matory process. The demonstration that the antinociception
observed was mediated by S100A9 action was confirmed by
adsorption of this protein in the cell-free exudates obtained
4 or 8 hours after the irritant injection.
The participation of neutrophils in the observed antino-
ciceptive eﬀect, as previously shown [24, 25], can be rein-
forced by results here shown with the cell-free exudates ob-
tained 24 and 48 hours after the glycogen injection, since they
did not induce antinociception with a decrease of polymor-
phonuclear cells and concomitant increase of mononuclear
cells.
The mechanism by which S100A9 induces antinocicep-
tion was not established yet. However, taking into account
that S100A9 deactivates activatedmacrophages [23], and that
the C-terminus of S100A9 murine inhibits phagocytosis and
spreading activities of adherent peritoneal cells [26], cells
involved in painful response by release of hyperalgesic cy-
tokines in the abdominal contortions model [27], the eﬀect
observed by S100A9 could be related with macrophage acti-
vation with consequent inhibition of secretion of algogenic
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factors by these cells. On the other hand, S100A9 could alter
the phenotype of macrophages for an “anti-inflammatory
cell” increasing the release of inhibitory cytokines, such as IL-
4 and IL-10, which are involved in inflammatory pain con-
trol.
Although several reports describe the presence of S100A9
in the initial phase of inflammatory response [36, 37], less is
known about its biological role in nociception process. Our
data strongly indicate that neutrophil-secreted S100A9 pro-
tein participates in inflammatory pain control.
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